190 related articles for article (PubMed ID: 12173939)
1. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
Casu B; Guerrini M; Naggi A; Perez M; Torri G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
Biochemistry; 2002 Aug; 41(33):10519-28. PubMed ID: 12173939
[TBL] [Abstract][Full Text] [Related]
2. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
Leali D; Belleri M; Urbinati C; Coltrini D; Oreste P; Zoppetti G; Ribatti D; Rusnati M; Presta M
J Biol Chem; 2001 Oct; 276(41):37900-8. PubMed ID: 11473122
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
6. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.
Lundin L; Larsson H; Kreuger J; Kanda S; Lindahl U; Salmivirta M; Claesson-Welsh L
J Biol Chem; 2000 Aug; 275(32):24653-60. PubMed ID: 10816596
[TBL] [Abstract][Full Text] [Related]
7. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
[TBL] [Abstract][Full Text] [Related]
8. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
[TBL] [Abstract][Full Text] [Related]
9. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
11. The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.
Liekens S; Bronckaers A; Belleri M; Bugatti A; Sienaert R; Ribatti D; Nico B; Gigante A; Casanova E; Opdenakker G; Pérez-Pérez MJ; Balzarini J; Presta M
Mol Cancer Ther; 2012 Apr; 11(4):817-29. PubMed ID: 22302099
[TBL] [Abstract][Full Text] [Related]
12. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis.
Li LY; Safran M; Aviezer D; Böhlen P; Seddon AP; Yayon A
Biochemistry; 1994 Sep; 33(36):10999-1007. PubMed ID: 7522051
[TBL] [Abstract][Full Text] [Related]
13. Interaction of heparins with fibroblast growth factors: conformational aspects.
Guerrini M; Hricovíni M; Torri G
Curr Pharm Des; 2007; 13(20):2045-56. PubMed ID: 17627538
[TBL] [Abstract][Full Text] [Related]
14. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis.
Ribatti D; Nico B; Morbidelli L; Donnini S; Ziche M; Vacca A; Roncali L; Presta M
J Vasc Res; 2001; 38(4):389-97. PubMed ID: 11455210
[TBL] [Abstract][Full Text] [Related]
15. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells.
Dell'Era P; Belleri M; Stabile H; Massardi ML; Ribatti D; Presta M
Oncogene; 2001 May; 20(21):2655-63. PubMed ID: 11420677
[TBL] [Abstract][Full Text] [Related]
16. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo.
Ribatti D; Nico B; Vacca A; Roncali L; Burri PH; Djonov V
Anat Rec; 2001 Dec; 264(4):317-24. PubMed ID: 11745087
[TBL] [Abstract][Full Text] [Related]
17. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
Pisano C; Aulicino C; Vesci L; Casu B; Naggi A; Torri G; Ribatti D; Belleri M; Rusnati M; Presta M
Glycobiology; 2005 Feb; 15(2):1C-6C. PubMed ID: 15496501
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
[TBL] [Abstract][Full Text] [Related]
19. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
[TBL] [Abstract][Full Text] [Related]
20. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.
Liekens S; Leali D; Neyts J; Esnouf R; Rusnati M; Dell'Era P; Maudgal PC; De Clercq E; Presta M
Mol Pharmacol; 1999 Jul; 56(1):204-13. PubMed ID: 10385702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
